Oncimmune Holdings PLC Appointment of Non-Executive Director (5860M)

TIDMONC

RNS Number : 5860M

Oncimmune Holdings PLC

13 January 2023

13 January 2023

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Appointment of Non-Executive Director

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, is pleased to announce that further to the announcement made on 7 December 2022, John Goold has been appointed to the Board of the Company as Non-Executive Director with immediate effect, following the successful completion of customary due diligence checks by the Company's Nominated Adviser.

Additional Information in respect of the AIM Rules

The following information regarding the appointment of John Howard Goold, aged 51, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 
 Current Directorships       Previous Directorships (within 
                              the last five years) 
 Freelands Finance Limited   Zeus Capital Limited 
  Kelso Group Holdings plc    Zeus Group Limited 
  Kelso Ltd                   Zeus Securities Limited 
                              Zeus Capital Investment Limited 
                            --------------------------------- 
 

As at the date of this announcement, John Goold holds 1,150,000 ordinary shares in the Company equivalent to 1.55% of the Company's issued share capital.

Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of John Goold.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser, Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT(R), can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT(R) Lung, targets a vast market estimated to grow to GBP3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABLGDBCGBDGXD

(END) Dow Jones Newswires

January 13, 2023 02:00 ET (07:00 GMT)